Predictors at Diagnosis for Start of Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis

被引：0
|
作者：
Hameed, M. [1 ]
Exarchou, S. [1 ]
Eberhard, A. [1 ]
Sharma, A. [1 ]
Bergstrom, U. [1 ]
Einarsson, J. [2 ]
Turesson, C. [1 ]
机构：
[1] Lund Univ, Rheumatol, Dept Clin Sci, Malmo, Sweden
[2] Lund Univ, Rheumatol, Dept Clin Sci, Malmo, Sweden
来源：
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2023年 / 52卷
关键词：
Rheumatoid arthritis; bDMARDs; Predictors;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP08
引用
收藏
页码：67 / 68
页数：2
相关论文
共 50 条
  • [41] Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis
    Giachi, Andrea
    Cugno, Massimo
    Gualtierotti, Roberta
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [42] THE IMPACT OF EDUCATION ON ADHERENCE TO TREATMENT WITH DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS PATIENTS
    Holc, I.
    Pahor, A.
    Gradisnik, S.
    Dai, K.
    Krajnc, M. Koren
    Grobelsek, V. Kovacic
    Dobnik, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 706 - 707
  • [43] Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review
    Giollo, Alessandro
    Bissell, Lesley-Anne
    Buch, Maya H.
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (07) : 697 - 708
  • [44] Persistence on Disease Modifying Anti-Rheumatic Drugs Among Taiwan Established Rheumatoid Arthritis Patients
    Liu, Yi-Han
    Lin, Tzu-Chieh
    Yang, Yea-Huei Kao
    Chang, Hui-Jen
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 73 - 73
  • [45] Rheumatoid arthritis pharmacotherapy and predictors of disease-modifying anti-rheumatic drug initiation in the early years of biologic use in Quebec, Canada
    Jean-Pascal Roussy
    Louis Bessette
    Elham Rahme
    Sasha Bernatsky
    Jean Légaré
    Jean Lachaine
    Rheumatology International, 2014, 34 : 75 - 83
  • [46] Rheumatoid arthritis pharmacotherapy and predictors of disease-modifying anti-rheumatic drug initiation in the early years of biologic use in Quebec, Canada
    Roussy, Jean-Pascal
    Bessette, Louis
    Rahme, Elham
    Bernatsky, Sasha
    Legare, Jean
    Lachaine, Jean
    RHEUMATOLOGY INTERNATIONAL, 2014, 34 (01) : 75 - 83
  • [47] IMPACT OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN LIPID PROFILE OF PSORIATIC ARTHRITIS PATIENTS
    Guajardo-Aldaco, Andrea L.
    Galarza-Delgado, Dionicio A.
    Azpiri-Lopez, Jose R.
    Colunga-Pedraza, Iris J.
    Cardenas-de la Garza, Jesus A.
    Arvizu-Rivera, Rosa I.
    Elizondo-Benitez, Maria F.
    Gonzalez-Gonzalez, Valeria
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [48] Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis
    Nell, VPK
    Machold, KP
    Eberl, G
    Stamm, TA
    Uffmann, M
    Smolen, JS
    RHEUMATOLOGY, 2004, 43 (07) : 906 - 914
  • [49] RACIAL DISPARITIES IN UTILIZATION OF BIOLOGIC AND DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN A CALIFORNIA MEDICAID POPULATION WITH RHEUMATOID ARTHRITIS
    Nichol, M. B.
    Wu, J.
    Harker, J. O.
    Knight, T. K.
    Wong, A. L.
    VALUE IN HEALTH, 2011, 14 (03) : A132 - A132
  • [50] Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis
    Sendaydiego, Xavier
    Gold, Laura S.
    Dubreuil, Maureen
    Andrews, James S.
    Reid, Pankti
    Liew, David F. L.
    Goulabchand, Radjiv
    Hughes, Grant C.
    Sparks, Jeffrey A.
    Jarvik, Jeffrey G.
    Singh, Siddharth
    Liew, Jean W.
    Singh, Namrata
    RHEUMATOLOGY, 2025,
12345